Novo Nordisk reported on July 31 that its experimental heart drug ziltivekimab did what it was designed to do biologically and produced no measurable clinical benefit. In a trial of more than 6,300 patients, the drug lowered inflammatory markers as expected but did not reduce cardiovascular death, non-fatal heart attack, or non-fatal stroke compared with placebo.
The hazard ratio was 0.99, with a 95 percent confidence interval of 0.88 to 1.11. In plain terms, the treated group and the placebo group had essentially identical outcomes.
-copy-29e15046.jpeg?w=600)
